Recently Added Drugs
1. Adlarity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12161767 | CORIUM | Systems and methods for long term transdermal administration |
Dec, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12168075 | CORIUM | Systems comprising a composite backing and methods for long term transdermal administration |
Dec, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 11, 2025 |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2022
Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type
Dosage: SYSTEM
More Information on Dosage
ADLARITY family patents
2. Alyftrek patent expiration
ALYFTREK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 9 months from now) | |
| US10239867 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US11639347 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US7645789 | VERTEX PHARMS INC | Indole derivatives as CFTR modulators |
May, 2027
(2 years from now) | |
| US8623905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(2 years from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(2 years from now) | |
| US7776905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2027
(2 years from now) | |
| US10047053 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(7 years from now) | |
| US8865902 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(7 years from now) | |
| US9181192 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(7 years from now) | |
| US9512079 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(7 years from now) | |
| US11066417 | VERTEX PHARMS INC | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
Feb, 2039
(13 years from now) | |
| US11873300 | VERTEX PHARMS INC | Crystalline forms of CFTR modulators |
Aug, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(3 months from now) | |
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(1 year, 3 months from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 9 months from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 9 months from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 9 months from now) | |
| US10022352 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US9974781 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US8598181 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(2 years from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(2 years from now) | |
| US8415387 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(2 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(4 years from now) | |
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(4 years from now) | |
| US10081621 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(6 years from now) | |
| US11578062 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(6 years from now) | |
| US10058546 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof |
Jul, 2033
(8 years from now) | |
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(8 years from now) | |
| US10206877 | VERTEX PHARMS INC | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
Apr, 2035
(10 years from now) | |
| US11951212 | VERTEX PHARMS INC | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
Apr, 2035
(10 years from now) | |
| US11866450 | VERTEX PHARMS INC | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
Feb, 2039
(13 years from now) | |
| US12186306 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2029 |
Drugs and Companies using DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM ingredient
NCE-1 date: 20 December, 2028
Market Authorisation Date: 20 December, 2024
Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 6 years and older who have at least one f508del mutation or another responsive mutation in the cftr gene with a pharmaceutical...
Dosage: TABLET
More Information on Dosage
ALYFTREK family patents
3. Arikayce Kit patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12168021 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(10 years from now) | |
| US12168022 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen
Dosage: SUSPENSION, LIPOSOMAL
More Information on Dosage
ARIKAYCE KIT family patents
4. Barhemsys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12194022 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(5 years from now) | |
| US12005042 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 27 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Prevention and treatment of post-operative nausea and vomiting; Prevention of post-operative nausea and vomiting
Dosage: SOLUTION
More Information on Dosage
BARHEMSYS family patents
5. Belrapzo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12138248 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 May, 2018
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of BELRAPZO before it's drug patent expiration?
More Information on Dosage
BELRAPZO family patents
6. Bendeka patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12138248 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-179) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage
BENDEKA family patents
7. Brixadi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161640 | BRAEBURN | Opioid formulations |
Jul, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2026 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 23 May, 2023
Treatment: A method of treating moderate to severe opioid use disorder by administering buprenorphine once weekly
Dosage: SOLUTION, EXTENDED RELEASE
More Information on Dosage
BRIXADI family patents
8. Bylvay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12187812 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-918) | Jun 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of treating cholestatic pruritus in patients 12 months or older suffering from alagille syndrome (algs)
Dosage: CAPSULE, PELLETS; CAPSULE
More Information on Dosage
BYLVAY family patents
9. Cabenuva Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178815 | VIIV HLTHCARE | Regimens for treating HIV infections and aids |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-184) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
CABENUVA KIT family patents
10. Cosela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12168666 | PHARMACOSMOS | Morphic forms of trilaciclib and methods of manufacture thereof |
Nov, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 12 February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: NA
Dosage: POWDER
More Information on Dosage
COSELA family patents
11. Crenessity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12128033 | NEUROCRINE | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine |
Jun, 2041
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10905690 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11311544 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11730739 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2029 |
| Orphan Drug Exclusivity(ODE-503) | Dec 13, 2031 |
Drugs and Companies using CRINECERFONT ingredient
NCE-1 date: 13 December, 2028
Market Authorisation Date: 13 December, 2024
Treatment: Adjunctive treatment of classic congenital adrenal hyperplasia (cah)
Dosage: CAPSULE; SOLUTION
More Information on Dosage
CRENESSITY family patents
12. Crexont patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12194150 | IMPAX | Levodopa dosing regimen |
Dec, 2041
(16 years from now) | |
| US12201596 | IMPAX | Levodopa dosing regimen |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 August, 2024
Treatment: Treatment of parkinson's disease; Treatment of parkinsonism that may follow manganese intoxication
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
CREXONT family patents
13. Drizalma Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12171742 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(12 years from now) | |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 July, 2019
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS
More Information on Dosage
DRIZALMA SPRINKLE family patents
14. Ensacove patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8551995 | XCOVERY | Kinase inhibitor compounds |
Feb, 2029
(3 years from now) | |
| US9296724 | XCOVERY | Substituted pyridazinecarboxamides as kinase inhibitors |
Jun, 2029
(4 years from now) | |
| US9126947 | XCOVERY | Substituted pyridazine carboxamide compounds |
Nov, 2031
(6 years from now) | |
| US10899744 | XCOVERY | Crystalline form of compound suppressing protein kinase activity, and application thereof |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2029 |
Drugs and Companies using ENSARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 18 December, 2028
Market Authorisation Date: 18 December, 2024
Treatment: Treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc) who have not previously received an alk-inhibitor
Dosage: CAPSULE
More Information on Dosage
ENSACOVE family patents
15. Femlyv patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178824 | MILLICENT PR | Orodispersible formulations |
Jun, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 22, 2027 |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 22 July, 2024
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING
More Information on Dosage
FEMLYV family patents
16. Gemtesa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12180219 | UROVANT | Process for preparing beta 3 agonists and intermediates |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
| New Indication(I-955) | Dec 18, 2027 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
GEMTESA family patents
17. Gimoti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12194008 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(4 years from now) | |
| US12194009 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 19, 2023 |
Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 June, 2020
Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis
Dosage: SPRAY, METERED
How can I launch a generic of GIMOTI before it's drug patent expiration?
More Information on Dosage
GIMOTI family patents
18. Glyxambi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178819 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage
GLYXAMBI family patents
19. Iheezo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11969403 | HARROW EYE | Topical formulations of chloroprocaine and methods of using same |
May, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 27, 2025 |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2022
Treatment: NA
Dosage: GEL
More Information on Dosage
IHEEZO family patents
20. Inqovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12195496 | OTSUKA | 2′-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same |
Oct, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2025 |
| Orphan Drug Exclusivity(ODE-316) | Jul 07, 2027 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 07 July, 2024
Market Authorisation Date: 07 July, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
INQOVI family patents
21. Invega Hafyera patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12208100 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 30, 2024 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 30 August, 2021
Treatment: Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose
Dosage: SUSPENSION, EXTENDED RELEASE
How can I launch a generic of INVEGA HAFYERA before it's drug patent expiration?
More Information on Dosage
INVEGA HAFYERA family patents
22. Kybella patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161653 | ABBVIE | Treatment of submental fat |
Feb, 2032
(6 years from now) | |
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Treatment: Improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as described in the approved labeling
Dosage: SOLUTION
How can I launch a generic of KYBELLA before it's drug patent expiration?
More Information on Dosage
KYBELLA family patents
23. Liqrev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12186321 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(13 years from now) | |
Drugs and Companies using SILDENAFIL CITRATE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening
Dosage: SUSPENSION
More Information on Dosage
LIQREV family patents
24. Lumisight patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11592396 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Sep, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2029 |
Drugs and Companies using PEGULICIANINE ACETATE ingredient
NCE-1 date: 17 April, 2028
Market Authorisation Date: 17 April, 2024
Treatment: NA
Dosage: POWDER
More Information on Dosage
LUMISIGHT family patents
25. Lybalvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12194035 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan
Dosage: TABLET
More Information on Dosage
LYBALVI family patents
26. Lynparza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178816 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Product(NP) | Aug 17, 2020 |
| New Indication(I-762) | Jan 12, 2021 |
| New Indication(I-776) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| New Indication(I-818) | Dec 27, 2022 |
| New Indication(I-831) | May 08, 2023 |
| New Indication(I-832) | May 19, 2023 |
| Orphan Drug Exclusivity(ODE-180) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-181) | Aug 17, 2024 |
| New Indication(I-885) | Mar 11, 2025 |
| Orphan Drug Exclusivity(ODE-226) | Dec 19, 2025 |
| New Indication(I-914) | May 31, 2026 |
| Orphan Drug Exclusivity(ODE-283) | Dec 27, 2026 |
| Orphan Drug Exclusivity(ODE-306) | May 08, 2027 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 17 August, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage
LYNPARZA family patents
27. Myhibbin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12194143 | AZURITY | Mycophenolate oral suspension |
Aug, 2039
(14 years from now) | |
Drugs and Companies using MYCOPHENOLATE MOFETIL ingredient
Market Authorisation Date: 01 May, 2024
Treatment: Prophylaxis of organ rejection
Dosage: SUSPENSION
More Information on Dosage
MYHIBBIN family patents
28. Nymalize patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12186308 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 10, 2020 |
| Orphan Drug Exclusivity(ODE-46) | May 10, 2020 |
Drugs and Companies using NIMODIPINE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry a...
Dosage: SOLUTION
How can I launch a generic of NYMALIZE before it's drug patent expiration?
More Information on Dosage
NYMALIZE family patents
29. Qbrelis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12186360 | AZURITY | Lisinopril formulations |
Nov, 2035
(10 years from now) | |
Drugs and Companies using LISINOPRIL ingredient
Market Authorisation Date: 29 July, 2016
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of QBRELIS before it's drug patent expiration?
More Information on Dosage
QBRELIS family patents
30. Qinlock patent expiration
Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12213967 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(15 years from now) | |
| US12213968 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
QINLOCK family patents
31. Radicava Ors patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12194025 | MITSUBISHI TANABE | Pharmaceutical composition for oral administration of edaravone and method of administering same |
Nov, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 12, 2025 |
| Orphan Drug Exclusivity(ODE-144) | May 12, 2029 |
Drugs and Companies using EDARAVONE ingredient
Market Authorisation Date: 12 May, 2022
Treatment: Treatment of amyotrophic lateral sclerosis by administering a liquid edaravone composition relative to the timing and type of food consumption
Dosage: SUSPENSION
How can I launch a generic of RADICAVA ORS before it's drug patent expiration?
More Information on Dosage
RADICAVA ORS family patents
32. Rytelo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12171778 | GERON | Methods of treating myelodysplastic syndrome |
Jun, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-482) | Jun 06, 2031 |
Drugs and Companies using IMETELSTAT SODIUM ingredient
Market Authorisation Date: 06 June, 2024
Treatment: Treatment of patients with myelodysplastic syndromes (mds) with transfusion-dependent anemia
Dosage: POWDER
More Information on Dosage
RYTELO family patents
33. Ryzumvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12201616 | FAMYGEN LIFE SCI | Methods and compositions for treatment of mydriasis |
Oct, 2039
(14 years from now) | |
| US12201615 | FAMYGEN LIFE SCI | Methods and compositions for treatment of mydriasis |
Dec, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 25, 2026 |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 25 September, 2023
Treatment: Treatment of pharmacologically-induced mydriasis
Dosage: SOLUTION
More Information on Dosage
RYZUMVI family patents
34. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12194016 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Treatment of excessive daytime sleepiness by administering solriamfetol to a subject having no or mild renal impairment
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
35. Tabrecta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12208101 | NOVARTIS PHARM | Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide |
Jul, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2025 |
| Orphan Drug Exclusivity(ODE-291) | May 06, 2027 |
Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient
NCE-1 date: 06 May, 2024
Market Authorisation Date: 06 May, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
TABRECTA family patents
36. Tadliq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12186322 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(13 years from now) | |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 17 June, 2022
Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability
Dosage: SUSPENSION
More Information on Dosage
TADLIQ family patents
37. Tarpeyo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12171882 | CALLIDITAS | Pharmaceutical compositions |
Jan, 2043
(17 years from now) | |
| US12171883 | CALLIDITAS | Pharmaceutical compositions |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2024 |
| Orphan Drug Exclusivity(ODE-389) | Dec 15, 2028 |
| Orphan Drug Exclusivity(ODE-464) | Dec 20, 2030 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 15 December, 2021
Treatment: Reduction of proteinuria in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression, by release of budesonide from the formulation
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
TARPEYO family patents
38. Tazverik patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12168015 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161645 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(6 years from now) | |
| US12168016 | EPIZYME INC | Aryl-OR heteroaryl-substituted benzene compounds |
Sep, 2031
(6 years from now) | |
| US12162865 | EPIZYME INC | Methods of treating cancer |
May, 2034
(9 years from now) | |
| US12168014 | EPIZYME INC | Method for treating cancer |
May, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating relapsed or refractory follicular lymphoma; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste h...
Dosage: TABLET
More Information on Dosage
TAZVERIK family patents
39. Tradjenta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178819 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
40. Tryngolza (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9127276 | IONIS PHARMS INC | Conjugated antisense compounds and their use |
May, 2034
(9 years from now) | |
| US9163239 | IONIS PHARMS INC | Compositions and methods for modulating apolipoprotein C-III expression |
May, 2034
(9 years from now) | |
| US9181549 | IONIS PHARMS INC | Conjugated antisense compounds and their use |
May, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9157082 | IONIS PHARMS INC | Modulation of apolipoprotein CIII (ApoCIII) expression |
Apr, 2032
(7 years from now) | |
| US9593333 | IONIS PHARMS INC | Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations |
Feb, 2034
(8 years from now) | |
Drugs and Companies using OLEZARSEN SODIUM ingredient
Market Authorisation Date: 19 December, 2024
Treatment: Use in reducing triglycerides in adults with familial chylomicronemia syndrome (fcs)
Dosage: SOLUTION
More Information on Dosage
TRYNGOLZA (AUTOINJECTOR) family patents
41. Ubrelvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12168004 | ABBVIE | Treatment of migraine |
Jan, 2035
(9 years from now) | |
| US12194030 | ABBVIE | Treatment of migraine |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in a patient undergoing treatment with a weak cyp3a4 inhibitor
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
42. Vancomycin Hydrochloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161690 | HIKMA | Glycopeptide compositions |
Nov, 2035
(10 years from now) | |
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 15 February, 2019
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
VANCOMYCIN HYDROCHLORIDE family patents
43. Vascepa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12171738 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Feb, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
| New Indication(I-819) | Dec 13, 2022 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Use of vascepa to lower triglycerides and ldl-c in an adult patient on statin therapy with cardiovascular-related disease and elevated triglyceride (tg) levels (about 200 mg/dl to about 500 mg/dl)
Dosage: CAPSULE
How can I launch a generic of VASCEPA before it's drug patent expiration?
More Information on Dosage
VASCEPA family patents
44. Vasostrict patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12186362 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | |
Drugs and Companies using VASOPRESSIN ingredient
Market Authorisation Date: 17 April, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of VASOSTRICT before it's drug patent expiration?
More Information on Dosage
VASOSTRICT family patents
45. Vivimusta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12208086 | AZURITY | Stable pharmaceutical compositions of bendamustine |
Jul, 2042
(17 years from now) | |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
VIVIMUSTA family patents
46. Vtama patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497718 | DERMAVANT SCI | Use of tapinarof for the treatment of atopic dermatitis |
Nov, 2039
(14 years from now) | |
| US11938099 | DERMAVANT SCI | Use of tapinarof for the treatment of atopic dermatitis |
Nov, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2027 |
| New Indication(I-956) | Dec 12, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 23 May, 2026
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older
Dosage: CREAM
More Information on Dosage
VTAMA family patents
47. Xdemvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12171750 | TARSUS | Isoxazoline parasiticide formulations and methods for treating blepharitis |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2028 |
Drugs and Companies using LOTILANER ingredient
NCE-1 date: 25 July, 2027
Market Authorisation Date: 24 July, 2023
Treatment: Treatment of demodex blepharitis via topical administration to an ocular surface
Dosage: SOLUTION/DROPS
More Information on Dosage
XDEMVY family patents
48. Xtandi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161628 | ASTELLAS | Combination therapy |
Feb, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 31, 2017 |
| New Indication(I-693) | Sep 10, 2017 |
| New Indication(I-786) | Jul 13, 2021 |
| New Indication(I-808) | Dec 16, 2022 |
| New Indication(I-926) | Nov 17, 2026 |
Drugs and Companies using ENZALUTAMIDE ingredient
NCE-1 date: 31 August, 2016
Market Authorisation Date: 31 August, 2012
Treatment: Treatment of patients with castration-resistant prostate cancer to whom rifampin is administered with the co-administration of a daily dose of 240 mg enzalutamide
Dosage: TABLET
How can I launch a generic of XTANDI before it's drug patent expiration?
More Information on Dosage
XTANDI family patents